Oral hygiene is often associated with brushing and flossing, but one important step that is sometimes overlooked is the use of mouthwash. For many, it is seen as an optional addition to their routine, ...

There must have been a time when you did not carry your toothbrush and found it safe to use someone else's. While you're most likely to avoid a stranger's toothbrush, sharing one with your sibling or ...

HIV impacts oral health. Infections and sores appear in the mouth. Canker sores and oral thrush are common. Oral hygiene is important for prevention. Antiretroviral therapy helps. Regular dental ...

If you regularly wake with a dry mouth, it is important to tackle hydrating it to reduce risk of further oral diseases. Dr ...

The chances of transmitting HIV through oral sex are very low, but it can happen. Preventive measures, such as condoms, can further reduce the risk. HIV transmits through some bodily fluids. The virus ...

Industrial juggernaut Author & Punisher has an album coming out in a week titled Nocturnal Birding. Everything we’ve heard of it thus far is heavy, oppressive, and atmospheric and the album’s final ...

Eli Lilly is releasing new Phase 3 trial results Tuesday. Drugmaker Eli Lilly says its daily oral GLP-1 pill may help people who have obesity and people with Type 2 diabetes lose approximately 23 ...

Allison DeAngelis is the East Coast biotech and venture capital reporter at STAT, reporting where scientific ideas and money meet. She is also co-host of the weekly biotech podcast, The Readout Loud.

The UAE has approved Tolebrutinib, the world’s first oral treatment for non-relapsing secondary progressive multiple sclerosis (SPMS). Developed to slow disability progression without relying on ...

After Eli Lilly’s phase 3 data drop for its oral GLP-1 asset orforglipron earlier this month, the Indianapolis drugmaker has unveiled the second half of the data package that will support the med’s ...

Viking Therapeutics has reported phase 2 data on its oral obesity drug candidate, linking the peptide to weight loss of up to 12.2% after 13 weeks. But, with 38% of patients discontinuing treatment at ...

In ATTAIN-2, orforglipron met the primary and all key secondary endpoints, with compelling efficacy results and a safety profile consistent with injectable GLP-1 medicines Participants with obesity or ...